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Hidradenitis suppurativa in a patient 
with an FGFR2 Missense Mutation
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Mutations in the fibroblast growth factor-receptor gene 2 (FGFR2) gene have been 
implicated in numerous diseases, including nevus comedonicus (NC) and naevoid 
acne that have somatic missense mutations in FGFR2 in the affected tissue. A patient 
presented in our department with unusual, innumerable large comedones throughout his 
back reminiscient of NC, as well as multifocal hidradenitis suppurativa and acne. Topical 
and systemic treatments were unsuccessful. Whole exome sequencing of blood-derived 
DNA detected a germline mutation in FGFR2 that was predicted to be damaging. This 
could explain the multifocal and severe nature of the disease. We suggest screening 
other, phenotypically similar patients for FGFR2 mutations. Our findings, once confirmed 
independently, could indicate that therapeutic modulation of FGFR signaling in the acne 
tetrad could be effective.
Keywords: acne, comedones, fibroblast growth factor-receptor gene 2, hidradenitis suppurativa, whole exome 
sequencing
Hidradenitis suppurativa (HS) is an inflammatory skin disease that affects roughly 1% of 
Europeans. It is characterized by painful abscesses, boils, cysts, and malodorous, pus-filled lesions 
in intertriginous regions (1, 2). It can follow autosomal dominant inheritance in some families, and 
mutations have been reported (3) in the gamma-secretase genes Presenilin-1 (PSEN1), Presenilin 
Enhancer-2 (PSENEN), and Nicastrin (NCSTN) in a minority (<7%) of cases. The remaining 
cohort are presumed to be sporadic or driven by other, as yet unidentified mutations. Nevus 
comedonicus (NC) is a rare (prevalence 1:45,000–1:100,000) epidermal nevus comprising of a 
group of dilated hair follicle openings filled with plugs of brownish-black oxidized keratin (4). 
It is usually localized on the head and neck and was initially described as “localized acne” (5). 
If it occurs as a part of the nevus comedonicus syndrome (NCS) (6), it can be generalized and 
form linear streaks. HS-like lesions have been observed in NCS (7). In some cases of NC, a 
somatic mutation in fibroblast growth factor-receptor gene 2 (FGFR2) has been identified, namely 
the Ser252Trp missense mutation (5). FGFR2 is expressed in keratinocytes, hair follicles, and 
sebaceous glands and has been implicated to induce hypercornification and comedogenesis (8). 
Germline FGFR2 mutations are also associated with acne, as seen in dominant Apert syndrome 
(9) (also comprising craniosynostosis, epiphyseal closure, and syndactyly) (10, 11). When occur-
ring as a mosaic, the acne lesions follow Blaschko’s lines (12), the pattern of embryological cell 
development and proliferation. In a recent case, a postzygotic mosaicism was found in exon 4 
of FGFR2 (c.758C>G, p.Pro253Arg) in low copy number. A similar mosaicism was also found 
in two other patients in p.Ser252Trp of exon 4 (8).
FiGuRe 1 | Widespread abscesses present in 49-year-old male patient. (a) Back of patient showing grouped comedones and hidradenitis suppurativa (HS) 
scars. (B) Inguinal scars. (C) Close-up of open HS lesions.
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A 49-year-old male construction worker presented with a 
29-year history of multiple abscesses in his buttock, inguinal, and 
axillary regions (Figure 1) and a history of severe post-pubertal 
acne conglobate. His back was studded with innumerable large 
comedones not unlike those seen in NC, however rather more 
spread out (Figure 1A), and with significant scarring. His condi-
tion had proved resistant to treatment with topical and systemic 
antibiotics, dapsone, retinoids, including acitretin and isotreti-
noin, zinc supplements and PUVA. Treatment with infliximab 
did have an effect on the inflammatory components; however, it 
was minimal and ultimately unsuccessful. Surgical interventions 
included excision of the left axilla and shoulder region and a 
transposition flap and excision of a pilonidal sinus.
The patient is an orphan. It is known that several other peo-
ple in his family including his father and brother had suffered 
from the same condition with different intensities; however, 
there is no contact between the patient and family. Requests 
to collect samples from family members were denied by the 
patient. Suspecting a potential genetic origin (13), we therefore 
performed whole exome sequencing on blood-derived DNA. A 
search for rare, deleterious mutations revealed that there was 
no such mutation present in any of the known HS-associated 
genes. However, a rare missense mutation in the FGFR2 gene 
was found in exon 5 (c.G492C, p.K164N, see Table  1). This 
mutation is predicted (14) to have pathological consequence 
on the protein by several prediction algorithms, namely SIFT 
(“deleterious,” lowest score 0), PolyPhen (“probably damag-
ing,” highest score 1), LoFtool (“probably damaging,” 0.00179), 
Condel (“deleterious,” 1.00), CADD (17.05), and SNPs&Go (73% 
probability). MutPred resulted in 63% probability for “damag-
ing,” and predicted (15) molecular features of the mutation are 
loss of methylation at K164 (P = 0.0069), loss of ubiquitination 
at K164 (P = 0.0081), loss of solvent accessibility (P = 0.0371), 
and loss of MoRF binding (not significant, P = 0.0575) as well as 
gain of sheet (not significant, P = 0.1451).
DisCussioN
In a patient with clinical features reminiscent of NCS, we found 
a new, rare heterozygous missense mutation in FGFR2, the gene 
for the keratinocyte growth factor (KGF) receptor. FGFR2, also 
known as CD332, was cloned in 1990 (16) and soon found to be 
the receptor for KGF. It has an extracellular part constructed of 
three immunoglobulin domains, a lipophilic transmembrane part, 
and a tyrosine kinase that extends in the cytoplasm. Fibroblast 
growth factors (FGF) can bind the extracellular domain and thus 
activate the tyrosine kinase. This leads to cell division and dif-
ferentiation. The isoform found in ectodermal tissues such as the 
skin is the FGFR2IIIb, also known as the KGF receptor. It binds 
FGF-7 and 10, also known as KGF 1 and 2, as well as FGF-1, -3, 
-22. Keratinocyte growth factors are potent mitogens for many 
epithelial cell types but lack detectable activity on fibroblasts or 
endothelial cells.
Germline mutations in FGFR2 underlie various craniosynos-
tosis syndromes (Table 2), and somatic mutations in the same 
gene have been reported in NC (5) and nevoid acne (9). We report 
taBle 2 | Diseases caused by FGFR2 mutations.
location phenotype phenotype MiM 
number
inheritance phenotype mapping key
10q26.13 Antley–Bixler syndrome without genital anomalies or disordered steroidogenesis 207410 AR 3
10q26.13 Apert syndrome 101200 AD 3
10q26.13 Beare-Stevenson cutis gyrata syndrome 123790 AD 3
10q26.13 Bent bone dysplasia syndrome 614592 AD 3
10q26.13 Craniofacial-skeletal-dermatologic dysplasia 101600 AD 3
10q26.13 Craniosynostosis, non-specific 3
10q26.13 Crouzon syndrome 123500 AD 3
10q26.13 Gastric cancer, somatic 613659 3
10q26.13 Jackson–Weiss syndrome 123150 AD 3
10q26.13 LADD syndrome 149730 AD 3
10q26.13 Pfeiffer syndrome 101600 AD 3
10q26.13 Saethre–Chotzen syndrome 101400 AD 3
10q26.13 Scaphocephaly and Axenfeld-Rieger anomaly NA 3
10q26.13 Scaphocephaly, maxillary retrusion, and mental retardation 609579 NA 3
10q26.13 Nevus comedonicus – Somatic none
taBle 1 | Fibroblast growth factor-receptor gene 2 (FGFR2) mutation identified in the patient.
Chr pos Ref alt exon Mutation MaF in 1KG, eVs, exaC
10 123310936 C G exon5 c.G492C, p.K164N 0.00
siFt polyphen Condel loFtool sNps&Go Mutpred CaDD
deleterious probably_damaging deleterious (1.0) probably damaging (0.00179) Disease (0.73) Disease (0.626) 17.1
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a germline mutation in FGFR2 that may contribute to explaining 
a generalized, rather than mosaic, NC-like, acneiform phenotype 
with additional features of HS. As documented above, the disease 
proved highly treatment resistant, which is a common feature in 
NC. FGFR inhibitors, which may directly address the genetically 
driven pathogenesis, exist but have not been reported in this 
context.
As the patient is a foundling, we could not determine the 
presence of the mutation in the rest of the family and were unable 
to obtain material for tissue expression studies. All available 
algorithms unanimously predict impaired protein function as a 
consequence of this mutation but follow-up studies, identifying 
further similar cases, are warranted to confirm this genotype–
phenotype correlation. HS is a phenotypically heterogeneous 
condition, and ongoing genetic investigation represents one 
important way of classifying subtypes and related conditions.
In summary, we have identified a germline mutation in FGFR2 
in a patient exhibiting features of generalized comedones and HS. 
Ongoing screening and functional interrogation of this group has 
the potential to further characterize the related phenotype and 
identify novel therapeutic targets.
Written informed consent was obtained from the patient to 
perform genetic analysis on the blood and to publish the resulting 
study.
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